FDA says manufacturing delays are constraining EpiPen supply

NEW YORK (Reuters) – The U.S. Food and Drug Administration added Mylan NV’s (MYL.O) EpiPen to its list of drugs in shortage on Wednesday, saying that manufacturing delays were creating intermittent supply constraints of the emergency allergy treatment.

The FDA said the status of Epipen, a lower dose version called EpiPen Jr, and Mylan’s own generic versions of those products were currently available, but that “supply levels may vary across wholesalers and pharmacies.”